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Regulation by hypoxia may underlie the expression of vascular endothelial growth factor in bladder cancer. We have
compared the distribution of vascular endothelial growth factor mRNA with a hypoxia marker, carbonic anhydrase 9 (CA IX).
vascular endothelial growth factor mRNA was analysed by in situ hybridisation and CA IX by immunochemistry in 22 cases of
bladder cancer. The relationship of microvessels to the distribution of CA IX was determined. In a separate series of 49
superﬁcial tumours, CA IX immunostaining was compared with clinico-pathological outcome. In superﬁcial and invasive disease
there was overlap in the expression of vascular endothelial growth factor and CA IX, CA IX being more widespread. Both
were expressed predominantly on the luminal surface, and surrounding areas of necrosis (invasive tumours). Expression of
both factors was greater in superﬁcial disease. Expression was absent within *80 mm of microvessels. Unlike vascular
endothelial growth factor, CA IX did not predict outcome in superﬁcial disease. Differential responses to reoxygenation
provide one explanation: vascular endothelial growth factor mRNA declined rapidly, while CA IX expression was sustained for
472 h. Expression of vascular endothelial growth factor mRNA in bladder tumours is consistent with hypoxic regulation and
suggests differential regulation in superﬁcial vs invasive disease. The expression of CA IX on the luminal surface justiﬁes
investigation of its utility as a therapeutic target/prognostic indicator.
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Tumour growth and metastasis are dependent upon angiogenesis
(Folkman, 1990). VEGF (vascular endothelial growth factor) is a
key regulator of this process (Ferrara and Davis-Smyth, 1997).
Expression of VEGF is an indicator of stage and outcome in a
number of tumour types and functional studies have conﬁrmed
its central role in angiogenesis and tumour growth (Zhang et al,
1995; Borgstrom et al, 1998). Previously we demonstrated that
expression of VEGF mRNA varies widely in human superﬁcial
bladder cancer and that the level of expression is predictive of
relapse and stage progression (Crew et al, 1997). The mechanisms
by which some superﬁcial tumours express VEGF mRNA at low
levels and others considerably higher (up to 345-fold more) remain
undetermined. An understanding of these mechanisms may shed
light on factors inﬂuencing a more angiogenic and therefore more
aggressive phenotype, and could provide new therapeutic or prog-
nostic approaches. Interestingly there are differences between
superﬁcial and invasive tumours in this regard. For example,
expression of the angiogenic factor thymidine phosphorylase (TP)
is signiﬁcantly higher in invasive than in superﬁcial bladder
tumours (O’Brien et al, 1995). In contrast, expression of VEGF
mRNA is four-fold higher in superﬁcial than in invasive tumours
though expression of VEGF protein does not differ (O’Brien et
al, 1995). This is indicative of differential regulation at the transla-
tional level and we have shown that expression of the eukaryotic
initiation factor-4E (eIF-4E) correlates with VEGF protein:mRNA
ratios in bladder tumours (Crew et al, 2000).
The regulation of VEGF by hypoxia has received considerable
attention. Tumour hypoxia is associated with rapid proliferation,
increased risk of metastasis and poor outcome (Brizel et al, 1996).
Regulation of gene expression by hypoxia may explain these effects.
Genes regulated by hypoxia include those that facilitate anaerobic
metabolism of glucose (Firth et al, 1994; Ebert et al, 1996), and
genes that enhance vascularity and oxygen delivery such as VEGF
(Schweiki et al, 1992). The transcription factor complexes HIF-1
(hypoxia inducible factor 1) and HIF-2 have emerged as key media-
tors of the hypoxic upregulation of these genes (Semenza, 1999).
Hypoxia is usually associated with acidic pH which may
promote tumour growth (Martinez-Zaguilan et al, 1996). Carbonic
anhydrases are important for regulation of pH and we demon-
strated recently that the tumour associated carbonic anhydrase 9
(CA9) is tightly regulated by the HIF-1 pathway (Wykoff et al,
2000). (CA9 refers to the carbonic anhydrase 9 gene including
any genomic sequence and mRNA, CA IX refers to the correspond-
ing protein). CA9 is induced strongly by hypoxia in a number of
tumour cell lines and the CA9 gene has a HIF-1 hypoxia response
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Expression of CA IX was compared with that of the bioreductive
hypoxia marker pimonidazole in a series of bladder transitional cell
carcinomas. The distribution of the two factors was strikingly simi-
lar although staining for CA IX was less extensive. Both CA IX and
pimonidazole were detected at the luminal surface of papillary
tumours and around areas of necrosis.
Because pathways of both pH regulation (CA9) and angiogenesis
(VEGF) are regulated by hypoxia, we have compared the expres-
sion patterns of CA IX and VEGF in superﬁcial and invasive
bladder cancers. Expression of VEGF was evaluated at the level
of mRNA for two reasons. First, VEGF protein is secreted and
therefore VEGF mRNA is a superior marker of the localisation
of VEGF production and regulation. Second, knowledge of the
localisation of the mRNA might facilitate understanding of the
mechanisms of VEGF mRNA upregulation in bladder cancer,
which have not been studied previously.
We demonstrate that VEGF mRNA is expressed most strongly
on the luminal surface of bladder tumours, and surrounding areas
of necrosis. This expression co-localises with areas of tumour
hypoxia as deﬁned by expression of CA IX in both superﬁcial
and invasive bladder tumours. We also show that expression of
CA IX is greater in superﬁcial than invasive tumours, consistent
with previous observations on the expression of VEGF mRNA
(O’Brien et al, 1995). These observations highlight differences
between superﬁcial and invasive bladder cancer, suggesting that
different pathways may regulate angiogenesis in superﬁcial and
invasive disease with the possibility that hypoxia is the driver of
angiogenesis in papillary tumours.
MATERIALS AND METHODS
Immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded tissue specimens collected by
standard surgical oncology procedures were obtained from the
Pathology Department, John Radcliffe Hospital, Oxford, UK.
Samples of normal bladder were taken from cadaveric organ
donors at the time of nephroureterectomy. CA IX immunostaining
using monoclonal antibody M75 was as described (Wykoff et al,
2000). Slides were viewed by two observers (K Turner and P
Watson). The CA IX score was derived from the product of (i)
the percentage of tumour cells staining for CA IX and (ii) the aver-
age intensity of that staining on a scale of 1 (least intense) to 3.
M75 antibody was from Pastorek (Pastorek et al, 1994).
Double staining for CA IX and CD34
CA IX immunostaining was as described with omission of counter-
staining (Wykoff et al, 2000). Sections were then incubated with
1:100 MoAb QBEnd10 (DAKO) (30 min) and then with goat
anti-mouse IgG (PO447, DAKO) (30 min) followed by APAAP
(30 min). The last two steps were repeated twice with 10 min incu-
bations. Visualisation was by New Fuchsin Red substrate (DAKO).
The distance from vessels to the edge of regions of CA IX staining
was assessed using an eyepiece graticule calibrated against a gradu-
ated slide. Vessels that lay obliquely to the plain of the section were
excluded.
In situ mRNA hybridisation
Speciﬁc localisation of VEGF mRNA was accomplished by in situ
hybridisation using an antisense riboprobe as described (Wykoff
et al, 2000).
CA IX and VEGF mRNA were studied in serial tissue sections.
In the majority of cases CA IX expression was more widespread
than expression of VEGF mRNA. For this reason, the percentage
of the tumour expressing VEGF mRNA that was also positive for
CA IX was quantiﬁed in each section. Sections were viewed by
two observers (K Turner and P Watson) and a consensus reached.
Effect of reoxygenation on hypoxically induced CA IX
protein/VEGF mRNA tissue culture
The A549 lung carcinoma cell line was obtained from ECACC
(European Collection of Animal Cell Cultures, UK). Cells were
grown in DMEM (Sigma) supplemented with 10% foetal calf serum
(Globepharm), L-glutamine (2 mM), penicillin (50 IU ml
71), and
streptomycin sulphate (50 mgm l
71). Studies of gene expression
were performed on cells approaching conﬂuence in normal growth
medium. Parallel incubations were performed on aliquots of cells in
normoxia (humidiﬁed air with 5% CO2) and hypoxia. Hypoxic
conditions were generated in a Napco 7001 incubator (Precision
Scientiﬁc) with 0.1% O2,5 %C O 2, and balance N2. Re-oxygenation
experiments were performed by exposure of cells to hypoxia for
16 h followed by a return to normoxia for the indicated time.
RNA analysis
Total RNA was extracted by a modiﬁed acid/guanidinium thiocya-
nate/phenol/chloroform method (RNAzol B; Cinna/Biotec
Laboratories), dissolved in hybridisation buffer (80% formamide,
40 mM PIPES, 400 mM sodium chloride, and 1 mM EDTA,
pH 8) and analysed by RNase protection assay (RPA). RPAs for
vascular endothelial growth factor-A (VEGF-A) and CA9 were
performed using
32P-labelled RNA probes transcribed using SP6
RNA polymerase from the previously described DNA templates
(Maxwell et al, 1999; Wykoff et al, 2000). RPAs were performed
on 30 mg total RNA using an internal control assay for U6 small
nuclear RNA as described (Maxwell et al, 1999).
Cell lysis and immunoblotting
Whole cell protein extracts were prepared from tissue culture cells by
10 shomogenisationindenaturingconditionsasdescribed(Wiesener
et al, 1998). For Western analysis, aliquots were separated by SDS-
polyacrylamide gel electrophoresis and transferred to Immobilon-P
membranes. CA IX was detected using the mouse monoclonal anti-
human CA IX antibody M75 (1:50) as described (Pastorekova et al,
1992). HRP-conjugated goat-anti-mouse immunoglobulin (DAKO)
(1:2000) was applied for 1 h at room temperature (RT). ECL Plus
(Amersham Pharmacia) was used for visualisation.
RESULTS
Expression of VEGF mRNA in bladder cancer
Expression of VEGF mRNA was examined by in situ hybridisation in
22 cases of bladder cancer selected to represent the range of stage and
grade in human bladder tumours (Table 1), and in two samples of
normal bladder. Expression of a control mRNA (b-actin) was veriﬁed
in each case as a marker of mRNA preservation (data not shown).
Neither of the samples of normal bladder showed any expression of
VEGFmRNA(datanotshown).Therewasconsiderableinter-tumour
variation in VEGF with no expression detected in four cases (one case
of isolated carcinoma insitu (CIS),two TaG1tumours, and oneT3G3
tumour). In the remaining cases expression was most intense on the
luminal surface of tumours. This expression was patchy, with areas
of strong and weak luminal expression within the same resected chip.
Enhanced luminal expression was particularly marked in superﬁcial
tumours: intense staining of the outer half of the transitional cell
epithelium was typical (approximately 50 mm from luminal surface
to core) (Figure 1). Increased luminal expression was also noted in
all chips of invasive tumour that contained surface epithelium.
However, this staining was substantially less intense and widespread
than in superﬁcial tumours (Figure 2). In several cases of invasive
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(8), 1276–1282tumour, in addition to luminal expression, there was enhanced
expression of VEGF within the invasive portion of the tumour. This
expression was observed primarily around areas of necrosis (Figure
2). Of the four cases of invasive bladder cancer in which there was
CIS in a separate biopsy, the CIS did not express VEGF in two cases
and was weakly positive in the remaining two cases.
Expression of CA IX
CA IX expression was evaluated by immunochemistry in the same
22 cases on serial sections. In 17 out of 18 cases in which VEGF
mRNA was detected, at least 50% of the areas that expressed VEGF
mRNA also expressed CA IX. Furthermore, the distribution of CA
IX and VEGF expression was strikingly similar (Figures 1 and 2).
Like VEGF mRNA, CA IX was expressed maximally on the luminal
surface of tumours and around regions of necrosis in invasive
tumours. In addition, whilst both superﬁcial and invasive tumours
showed luminal enhancement, this was much more marked in
superﬁcial tumours. Expression of CA IX in the sections of CIS
from patients with invasive tumours matched that of VEGF. CA
IX was not detected in the normal bladder specimens, nor was it
detected in samples from the patient with isolated CIS.
In addition to these 22 cases, CA IX immunostaining was
performed on a further ﬁve cases of isolated CIS, three normal
bladders and four normal ureters. Of these, one case of CIS showed
very weak luminal staining, but the remainder of the CIS cases and
all sections of normal urothelium were negative for CA IX expres-
sion. In summary, in a total of 10 cases of CIS, immunostaining
for CA IX was weak in three, and absent in seven.
Relationship of CA IX to microvessels
In order to elucidate factors that might inﬂuence the expression of
CA IX in bladder cancer, we examined the relationship between
expression of CA IX and tumour microvessels. The distribution
of CD 34 staining (as a marker of blood vessels) was compared
to that of CA IX staining in the same sections for a subset of cases
(52 vessels were assessed in 12 different cases, Figure 3). In super-
ﬁcial and invasive tumours, CA IX expression was typically
detected in regions of the tumour that were a mean distance of
80 mm from a blood vessel (standard deviation=44 mm).
Relationship of CA IX expression in superﬁcial bladder
cancer to other clinical and prognostic factors
We have demonstrated previously that VEGF mRNA expression
on RNAse protection was predictive of recurrence and stage
progression in a series of 55 superﬁcial bladder tumours (Ta/T1,
G1/G2) (Crew et al, 1997). Given the association between CA
IX and VEGF expression, we aimed to establish whether CA IX
expression was also predictive of outcome in these cases. There-
fore, sections from 49 of these previously studied cases were
stained for CA IX and expression was scored semi-quantitatively
(range=0–225, median=30, cases were split into ‘low’ CA IX
(i.e. score 5median (n=22), and ‘high’ CA IX (i.e. score
4median (n=27)). Comparisons were made between CA IX
expression and other factors that we had determined previously
including expression of VEGF mRNA (by RNAse protection),
tumour grade, risk of recurrence, time to recurrence, and risk
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Table 1 Expression of CA IX protein and VEGF mRNA in human bladder cancer
VEGF in situ CA IX 450%
Patient Tumour stage/grade hybridisation immunostaining overlap
1 CIS 7ve 7ve na
2T a G 1 7ve luminal na
3T a G 1 7ve luminal na
4 Ta G2 luminal luminal y
5 T1 G1 luminal luminal y
6 T1 G2 luminal luminal y
7 T1 G2 luminal luminal y
8 T1 G2 luminal luminal y
9 T1 G2 luminal luminal y
10 T2 G2 luminal, and
perinecrotic
luminal, and
perinecrotic
y
11 T2 G2 luminal and
invasive tumour
luminal and
invasive tumour
y
12 T2 G3 luminal luminal y
13 T2 G3 luminal luminal y
14 T2 G3 luminal, and
perinecrotic
luminal but
sparse
n
15 T2 G2, CIS in separate biopsy perinecrotic
CIS 7ve
perinecrotic
CIS 7ve
y
16 T2 G2, CIS in
separate biopsy
perinecrotic
CIS weakly positive
perinecrotic
CIS weakly positive
y
17 T2 G2 luminal and
perinecrotic
luminal and
perinecrotic
y
18 T2 G3 luminal and
perinecrotic
luminal and
perinecrotic
y
19 T2 G3 invasive tumour invasive tumour y
20 T2 G3, CIS in
separate biopsy
luminal and
perinecrotic
CIS 7ve
luminal and
perinecrotic
CIS 7ve
y
21 T3 G3 7ve 7ve na
22 T4 G3, CIS in
separate biopsy
luminal, CIS
weakly positive
luminal, CIS
weakly positive
y
In a series of 22 human bladder tumours of a range of stage and grade the location of expression of VEGF was
assessed by in situ hybridisation of mNRA. In serial sections expression of CA IX was assessed by immuno-
chemistry using monoclonal antibody M75. In each case the percentage of the tumour expressing VEGF
mRNA that was also positive for CA IX (i.e. the overlap) was quantiﬁed. y=yes; n=no; na=not applicable.
Expression of hypoxia inducible genes in bladder cancer
KJ Turner et al
1278
British Journal of Cancer (2002) 86(8), 1276–1282 ã 2002 Cancer Research UKof stage progression (Table 2). Although we had observed concor-
dance of the focal staining pattern in superﬁcial tumours, the
total level of VEGF mRNA as assessed by RNAse protection did
not correlate statistically with the CA IX score in these cases.
No signiﬁcant associations were found between CA IX staining
and any other of these parameters when assessed by both contin-
uous and cutpoint analysis.
Temporal relationship of CA IX/VEGF expression to
hypoxia and reoxygenation
Though there was striking overlap in the expression of CA IX and
VEGF, there were differences in the extent of the expression of
these two factors. Speciﬁcally, CA IX was generally expressed over
a greater area of the tumour than VEGF mRNA, and VEGF but not
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y Figure 1 Expression of CA IX protein (A,C) and VEGF mRNA (B,D) in superﬁcial bladder cancer at low power (reduced from610) (A,B) and high
power (reduced from640) (C,D).
Figure 2 Expression of CA IX protein (A,C) and VEGF mRNA (B,D) in invasive bladder cancer showing perinecrotic (A,B) and luminal expression
(C,D). Reduced from640.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(8), 1276–1282CA IX was predictive of time to recurrence and risk of stage
progression in Ta/T1 disease. We therefore investigated any differ-
ences in regulation that might underlie these observations. In
particular we investigated the temporal relationship between
expression of CA IX/VEGF and hypoxia and reoxygenation. To
our knowledge, there are no currently available cell lines derived
from superﬁcial human bladder tumours. Previously we had been
unable to detect hypoxic induction of CA IX in invasive bladder
cancer cell lines (Wykoff et al, 2000), which is consistent with
the low level of CA IX expression observed in invasive tumours
in this study. For these reasons the A549 lung carcinoma cell line,
which shows marked hypoxic induction of both VEGF and CA9,
was chosen for these studies. Interestingly, whilst CA9 mRNA
and CA IX protein, and VEGF mRNA were induced by hypoxia,
they differed markedly in their response to reoxygenation (Figure
4). Detection of CA IX protein remained constant for at least
72 h but both CA9 mRNA and VEGF mRNA declined rapidly,
reaching normoxic levels of expression within 8 h.
DISCUSSION
Angiogenesis plays a key role in the pathogenesis of bladder cancer:
microvessel density is a prognostic indicator in invasive bladder
cancer (Bochner et al, 1995; Jaeger et al, 1995), expression of the
angiogenic factors bFGF (basic ﬁbroblast growth factor), TGFb
(transforming growth factor b), midkine, and HGF (hepatocyte
growth factor) is elevated in patients with bladder cancer (reviewed
in Jones and Fujiyama, 1999) and VEGF expression is predictive of
stage progression and relapse in superﬁcial tumours (Crew et al,
1997).
Current attention is focused on the upstream events that govern
expression of angiogenic mediators. Hypoxia has emerged as a
potent stimulus in this regard, with hypoxia inducible transcription
factors regulating many aspects of this hypoxic response, including
expression of VEGF. The activity of the HIF pathway can also be
modulated by genetic inﬂuences such as mutations in the VHL
gene and other oncogenes (Maxwell et al, 1999), and by growth
factors (Semenza, 2000).
In this study we have investigated the relationship between
expression of VEGF and CA IX, having shown previously that
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Figure 3 Relationship of CA IX expression to microvessels in superﬁcial
(A) and invasive bladder cancer (B). Reduced from640.
Table 2 Relationship of CA IX expression in human bladder cancer to other clinicopathological parameters
Recurrence at Time to recurrence Mean time to
VEGF mRNA
a Grade 6 months in months Progression progression in months
Median (range) (% G1) (%) Mean (s.d.) (% progressed) Mean (s.d.)
Low CA IX score 62.5 (4–242) 27 55 6.8 (6.7) 27 9.3 (5.8)
High CA IX score 91 (1–345) 19 48 5.7 (4.9) 19 6.4 (3.5)
Expression of CA IX was determined in a series of 49 superﬁcial (Ta/T1, G1/G2) bladder tumours by immunohistochemistry using antibody M75. The CA IX
score was derived from the product of (i) the percentage of tumour cells staining for CA IX and (ii) the average intensity of that staining on a scale of 1 (least
intense) to 3. Cases were split into ‘low’ CA IX (i.e. score 5 median (n=22)), and ‘high’ CA IX (i.e. score 4 median (n=27)). Comparisons were made
between CA IX expression and other factors that we had determined previously including expression of VEGF mRNA (by RNAse protection), tumour
grade, risk of recurrence, time to recurrence, and risk of stage progression. There were no signiﬁcant differences in the variables between tumours with
high and low CA IX scores.
aArbitrary units.
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Figure 4 Expression of CA IX protein (by Western blotting), and VEGF
mRNA/CA9 mRNA (by RNAse protection) in A549 lung carcinoma cells
after growth under hypoxic conditions and then subsequent reoxygenation.
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British Journal of Cancer (2002) 86(8), 1276–1282 ã 2002 Cancer Research UKCA 9 is upregulated by HIF. We demonstrate that expression of
VEGF mRNA localises to areas of the tumour that also express
CA IX in both superﬁcial and invasive bladder cancers. These
observations suggest that expression of VEGF in human bladder
cancer is determined by tumour hypoxia and may be mediated
via the HIF pathway.
Expression of both VEGF and CA IX was most intense on the
luminal surface of tumours. Malignant transitional epithelium is
many times thicker than transitional cell epithelium in normal
bladder. The reduced oxygen tension that is associated with this
increased distance from vessels may enhance expression of VEGF.
Increasingly, superﬁcial and invasive bladder cancers are
regarded as distinct pathological entities and a two-pathway model
for bladder tumour development has been proposed (see Lee and
Droller, 2000 for review). In keeping with this, superﬁcial and inva-
sive bladder tumours differ in their expression of angiogenic
mediators. For example, expression of VEGF is four-fold higher
in superﬁcial tumours than in invasive tumours but expression
of thymidine phosphorylase is 33 times higher in invasive tumours
(O’Brien et al, 1995). In concordance with these results, we show
here that expression of VEGF mRNA is more widespread in super-
ﬁcial tumours than in invasive tumours.
The localisation, shown here for the ﬁrst time, of VEGF mRNA
on the luminal surface of bladder tumours explains the strong rela-
tionship we have found previously between urinary and tumour
VEGF protein, and the relationship of urinary VEGF to recurrence
(Crew et al, 1999). Expression of CA IX/VEGF mRNA at the lumi-
nal surface of invasive tumours was markedly less than that on the
luminal surface of superﬁcial tumours, even in regions of equiva-
lent distance from vessels. In addition, expression of CA IX/
VEGF mRNA was observed around areas of necrosis in invasive
tumours, a phenomenon that we have observed in tumours of
the breast, ovary, and head and neck (Wykoff et al, 2000). This
perinecrotic expression of CA IX/VEGF was also markedly less
intense than that observed on the luminal surface of superﬁcial
tumours, even though microenvironmental hypoxia is the likely
precipitant. These data therefore suggest that there is relatively less
activation of hypoxia regulated transcription pathways in invasive
tumours. This apparent difference between the two tumour types
adds to the evidence that superﬁcial and invasive bladder cancer
represent different disease processes.
Support for this hypothesis comes from our observations in CIS,
which is currently regarded as a progenitor of the invasive rather
than superﬁcial phenotype (Lee and Droller, 2000). Like invasive
tumours, expression of VEGF/CA IX in CIS was substantially less
than that seen in superﬁcial bladder cancer, even though the tran-
sitional epithelium in CIS was equivalent in thickness to superﬁcial
bladder cancer.
Expression of CA IX was generally more widespread than that of
VEGF mRNA, and VEGF but not CA IX was predictive of relapse
and stage progression in our series of superﬁcial bladder tumours.
There are several potential explanations for this discrepancy. First,
the difference in distribution may reﬂect different temporal
responses to cellular hypoxia. Whilst both factors were strikingly
induced by 16 h of hypoxia in tissue-culture cells, the level of
VEGF mRNA declined rapidly upon reoxygenation (in accordance
with a previous description (Schweiki et al, 1992)) whereas CA IX
protein levels remained high during reoxygenation for at least 72 h.
Therefore, the expression of VEGF mRNA observed in bladder
tumours may reﬂect current hypoxia, whereas expression of CA
IX may represent more chronic hypoxia. Second, whilst expression
of CA IX may facilitate survival under adverse pH, expression of
VEGF enhances growth and implantation. Hypoxia stimulates the
expression of both factors, but the level of expression of each factor
will vary and the factor that most favours tumour growth or
implantation is most likely to correlate with adverse outcome.
Third, in addition to regulation by HIF, CA9 and VEGF most likely
have other dissimilar mechanisms of regulation. For instance,
VEGF expression in hypoxia is also inﬂuenced by the RNA binding
protein HuR that stabilises VEGF mRNA (Levy et al, 1998).
This study emphasises the importance of hypoxia in deﬁning the
patterns of gene expression in bladder cancer. It also adds to the
growing body of evidence that superﬁcial and invasive bladder
cancer exhibit signiﬁcant biological differences. In particular, the
former demonstrate a much more marked luminal expression of
hypoxia inducible genes. Expression of extracellular carbonic anhy-
drases is likely to affect microenvironmental pH and in doing so
may promote tumour growth (Martinez-Zaguilan et al, 1996).
Carbonic anhydrase inhibitors inhibit the invasion of renal cancer
cells in vitro and synergise with chemotherapeutic agents in animal
models (Teicher et al, 1993; Parkkila et al, 2000). The high
frequency and marked enhancement of CA IX expression in super-
ﬁcial bladder cancer reported here, combined with the relative
absence in normal transitional epithelium, suggests that investiga-
tion into the utility of CA IX as a therapeutic target in this
context is warranted. Furthermore, since CA IX is a transmem-
brane protein, measurement of shed protein in the urine could
be a potential marker of recurrence.
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